Topics Presented this February 2018 at RNA Therapeutics
Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis?
Have questions answered during our two sessions presented by ProQR Therapeutics and University of Oxford.
Exploiting Exosomes for Therapeutic and Diagnostic Applications | Day 2 | @16:40
This presentation will examine the translational applications of exosome research, including biomarker discovery and drug delivery. The session will consider and evaluate of the important advantages compared to other nanoparticulate drug delivery systems and look at ways of overcoming potential problems with component characterization and immune reactions.
Presented by: Samir EL Andaloussi, Assistant Professor, Karolinska Institutet and Research Fellow, University of Oxford
RNA Therapeutics for Patients with Cystic Fibrosis: QR-010 and Beyond | Day 1 | @11:00
This session will explore the opportunities that RNA therapeutics may bring for patients with cystic fibrosis. The evidence for QR-010 as a meaningful RNA therapeutic for patients with cystic fibrosis will be discussed, looking specifically at the F508del mutation. Other mutations will also be explored while looking at RNA therapeutic approaches for patients with cystic fibrosis.
Presented by: Noreen Roth Henig, Chief Medical Officer, ProQR Therapeutics
- Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA.
- Learn how CureVac’s sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA.
- Discover STORM Therapeutics’ innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology.
- Expand knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acidbased technologies.
- Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches.
For those looking to attend there is currently a £200 early-bird saving, ending November 30th.
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Topics Presented this February 2018 at RNA Therapeutics here
News-ID: 824116 • Views: 499
More Releases from SMi Group
Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference
SMi reports: Registration is now open for the 4th annual Ophthalmic Drugs Conference, taking place in London on the 23rd-24th November 2020. SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd-24th of November 2020, in London. The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire
US Air Force to Present Briefing on New PNT Constellation, NTS-3, at Military PN …
The US Space Force's new PNT constellation, Navigation Technology Satellite 3 (NTS-3), is designed to provide resilience to Global Navigation Satellite Systems by bringing online the M-Code, a long-delay signal that's more resilient to jamming. Not only is NTS-3 able to resist jamming, but its satellites can also be redeployed to provide coverage where it’s most needed. Currently being built by L3Harris under an $84 million contract, the constellation is expected
Fraunhofer Institute and German Aerospace Center To Brief on German SSA Perspect …
SMi Reports: The Fraunhofer Institute and German Aerospace Center (DLR) will be providing perspectives of German space situational awareness, including programme updates on TIRA and GESTRA The Fraunhofer Institute is currently operating the Tracking and Imaging Radar (TIRA) and developing the German Experimental Space Surveillance and Tracking Radar (GESTRA), both of which are essential parts of German military and civil SSA programmes. TIRA provides data about not only highly precise orbital
British Army to present on Maximising Tactical Awareness through Comprehensive A …
This year, it was announced that the British Army is facing a “modernisation challenge” as it looks to balance buying new equipment with upgrading its legacy fleet. A part of this is to continue with plans to update the capabilities of legacy vehicles Warrior and Challenger 2. The UK plans to upgrade 170 Challenger 2 MBTs with a life extension programme (LEP) to continue their utility through till 2035, and
More Releases for RNA
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and